Allergy Therapeutics PLC Trading Update (0338E)
13 July 2016 - 4:00PM
UK Regulatory
TIDMAGY
RNS Number : 0338E
Allergy Therapeutics PLC
13 July 2016
13 July 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Trading Update
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, today
provides a trading update for the year ended 30 June 2016 ahead of
its Preliminary Results to be announced in September 2016.
Financials
Reported revenues are expected to be GBP48.5m (2015: GBP43.2m),
slightly ahead of current market expectations. This represents a
growth of 12%* despite the negative impact from the weakening Euro
during most of the year. At constant currency, this represents a
growth of 19%* for the year. This solid growth has been against a
flat market backdrop and has allowed the Company to increase its
market share two percentage points from 10% to 12% on average
across its key European markets. The main contributions in terms of
market share gains for the Company have come from Germany, Austria,
Spain and the UK.
Product
Allergy Therapeutics' market penetration is consistent across
the product portfolio, particularly from Pollinex Quattro, Oralvac
(which has benefited from a competitor situation) and our newer
products entering the market including Acarovac and Synbiotics.
The Company expects strong revenue growth to continue for
several years and aims to achieve a leading European market
position in the allergoid subcutaneous immunotherapy product (SCIT)
market before 2020.
Pipeline
In Europe, the development program for PQ Birch is on track and
the Pivotal Phase III study is planned to start in H1 2017. For the
US, the Company will perform another dose ranging study for PQ
Grass in order to ensure that the best dose is chosen for the final
Phase III study. Acarovac Quattro development is on track and
initiation of Phase I studies is expected to start in H2 2016.
Finally, the proof of concept study for the novel vaccine, Polyvac
Peanut, is progressing according to plan.
Commenting on the positive trading update, Manuel Llobet, Chief
Executive Officer of Allergy Therapeutics, said:
Our strong sales growth of 19%* at constant rates and further
gain in market share of two points to 12% shows that our ambition
to build a world-leading portfolio of aluminium-free,
patient-friendly vaccines is gaining increased traction. We
continue to invest in our business and remain on course to become
the leading company in the subcutaneous segment. We are also very
excited about the commercial opportunities in our current broad
portfolio."
*The growth figures include 3% which relates to the acquisition
of the Alerpharma business in June 2015.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura
Thornton
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information please
see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTLIFFEDDIVLIR
(END) Dow Jones Newswires
July 13, 2016 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024